Wall Street brokerages predict that Lantheus Holdings, Inc. (NASDAQ:LNTH) will post ($0.01) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Lantheus’ earnings, with the lowest EPS estimate coming in at ($0.02) and the highest estimate coming in at $0.00. Lantheus reported earnings of $0.36 per share in the same quarter last year, which would indicate a negative year over year growth rate of 102.8%. The company is expected to announce its next earnings results on Thursday, April 29th.
According to Zacks, analysts expect that Lantheus will report full year earnings of $0.37 per share for the current financial year, with EPS estimates ranging from $0.35 to $0.38. For the next year, analysts expect that the company will report earnings of $0.85 per share, with EPS estimates ranging from $0.80 to $0.90. Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Lantheus.
Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, February 25th. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.04. Lantheus had a net margin of 0.12% and a return on equity of 11.05%.
Shares of LNTH stock opened at $21.05 on Monday. The company’s 50-day moving average price is $19.71 and its 200-day moving average price is $15.51. The company has a current ratio of 2.25, a quick ratio of 1.79 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 263.16 and a beta of 1.32. Lantheus has a twelve month low of $10.52 and a twelve month high of $21.99.
In related news, CFO Robert J. Jr. Marshall sold 2,280 shares of the business’s stock in a transaction dated Thursday, March 4th. The shares were sold at an average price of $18.40, for a total value of $41,952.00. Following the sale, the chief financial officer now directly owns 76,985 shares in the company, valued at approximately $1,416,524. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael P. Duffy sold 1,737 shares of the business’s stock in a transaction dated Thursday, March 4th. The shares were sold at an average price of $18.40, for a total transaction of $31,960.80. The disclosure for this sale can be found here. Over the last 90 days, insiders purchased 4,000 shares of company stock worth $65,820 and sold 40,267 shares worth $740,935. 2.08% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of LNTH. Clearbridge Investments LLC purchased a new stake in Lantheus during the fourth quarter worth about $13,221,000. Russell Investments Group Ltd. increased its stake in Lantheus by 2,777.5% during the fourth quarter. Russell Investments Group Ltd. now owns 855,824 shares of the medical equipment provider’s stock worth $11,541,000 after purchasing an additional 826,082 shares during the period. Private Capital Management LLC increased its stake in Lantheus by 513.4% during the third quarter. Private Capital Management LLC now owns 952,994 shares of the medical equipment provider’s stock worth $12,074,000 after purchasing an additional 797,633 shares during the period. Peregrine Capital Management LLC increased its stake in Lantheus by 127.5% during the fourth quarter. Peregrine Capital Management LLC now owns 1,154,298 shares of the medical equipment provider’s stock worth $15,571,000 after purchasing an additional 646,803 shares during the period. Finally, Great Point Partners LLC purchased a new stake in Lantheus during the third quarter worth about $7,535,000. Institutional investors own 84.95% of the company’s stock.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.
Read More: Different Options Trading Strategies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.